193 related articles for article (PubMed ID: 32238734)
1. The Thrombopoietin Receptor Agonist Lusutrombopag Is Effective for Patients with Chronic Liver Disease and Impaired Renal Function.
Takeuchi H; Furuichi Y; Yoshimasu Y; Kasai Y; Abe M; Sugimoto K; Itoi T
J Nippon Med Sch; 2021 Jan; 87(6):325-333. PubMed ID: 32238734
[TBL] [Abstract][Full Text] [Related]
2. Avatrombopag and lusutrombopag for thrombocytopenia in people with chronic liver disease needing an elective procedure: a systematic review and cost-effectiveness analysis.
Armstrong N; Büyükkaramikli N; Penton H; Riemsma R; Wetzelaer P; Huertas Carrera V; Swift S; Drachen T; Raatz H; Ryder S; Shah D; Buksnys T; Worthy G; Duffy S; Al M; Kleijnen J
Health Technol Assess; 2020 Oct; 24(51):1-220. PubMed ID: 33108266
[TBL] [Abstract][Full Text] [Related]
3. Relationship between response to lusutrombopag and splenic volume.
Uojima H; Arase Y; Itokawa N; Atsukawa M; Satoh T; Miyazaki K; Hidaka H; Sung JH; Kako M; Tsuruya K; Kagawa T; Iwakiri K; Horie R; Koizumi W
World J Gastroenterol; 2018 Dec; 24(46):5271-5279. PubMed ID: 30581275
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of Lusutrombopag in Patients with Mild to Moderate Thrombocytopenia.
Tsuji Y; Kawaratani H; Ishida K; Kaya D; Kubo T; Fujinaga Y; Sawada Y; Takaya H; Shimozato N; Kaji K; Namisaki T; Moriya K; Akahane T; Yoshiji H
Dig Dis; 2020; 38(4):329-334. PubMed ID: 31655803
[TBL] [Abstract][Full Text] [Related]
5. Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (L-PLUS 2).
Peck-Radosavljevic M; Simon K; Iacobellis A; Hassanein T; Kayali Z; Tran A; Makara M; Ben Ari Z; Braun M; Mitrut P; Yang SS; Akdogan M; Pirisi M; Duggal A; Ochiai T; Motomiya T; Kano T; Nagata T; Afdhal N
Hepatology; 2019 Oct; 70(4):1336-1348. PubMed ID: 30762895
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic/Pharmacodynamic Modelling and Simulation of Lusutrombopag, a Novel Thrombopoietin Receptor Agonist, for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Invasive Procedures.
Katsube T; Shimizu R; Fukuhara T; Kano T; Wajima T
Clin Pharmacokinet; 2019 Nov; 58(11):1469-1482. PubMed ID: 31055790
[TBL] [Abstract][Full Text] [Related]
7. A randomized controlled trial of lusutrombopag in Japanese patients with chronic liver disease undergoing radiofrequency ablation.
Tateishi R; Seike M; Kudo M; Tamai H; Kawazoe S; Katsube T; Ochiai T; Fukuhara T; Kano T; Tanaka K; Kurokawa M; Yamamoto K; Osaki Y; Izumi N; Imawari M
J Gastroenterol; 2019 Feb; 54(2):171-181. PubMed ID: 30105510
[TBL] [Abstract][Full Text] [Related]
8. Real-life experience of lusutrombopag for cirrhotic patients with low platelet counts being prepared for invasive procedures.
Takada H; Kurosaki M; Nakanishi H; Takahashi Y; Itakura J; Tsuchiya K; Yasui Y; Tamaki N; Takaura K; Komiyama Y; Higuchi M; Kubota Y; Wang W; Okada M; Shimizu T; Watakabe K; Enomoto N; Izumi N
PLoS One; 2019; 14(2):e0211122. PubMed ID: 30768601
[TBL] [Abstract][Full Text] [Related]
9. Impact of Anti-GPIIb/IIIa Antibody-Producing B Cells as a Predictor of the Response to Lusutrombopag in Thrombocytopenic Patients with Liver Disease.
Wada N; Uojima H; Satoh T; Okina S; Iwasaki S; Shao X; Takiguchi H; Arase Y; Itokawa N; Atsukawa M; Miyazaki K; Hidaka H; Kako M; Kagawa T; Iwakiri K; Horie R; Suzuki T; Koizumi W
Dig Dis; 2021; 39(3):234-242. PubMed ID: 32759604
[TBL] [Abstract][Full Text] [Related]
10. Lusutrombopag Reduces Need for Platelet Transfusion in Patients With Thrombocytopenia Undergoing Invasive Procedures.
Hidaka H; Kurosaki M; Tanaka H; Kudo M; Abiru S; Igura T; Ishikawa T; Seike M; Katsube T; Ochiai T; Kimura K; Fukuhara T; Kano T; Nagata T; Tanaka K; Kurokawa M; Yamamoto K; Osaki Y; Izumi N; Imawari M
Clin Gastroenterol Hepatol; 2019 May; 17(6):1192-1200. PubMed ID: 30502505
[TBL] [Abstract][Full Text] [Related]
11. Lusutrombopag is effective and safe in patients with chronic liver disease and severe thrombocytopenia: a multicenter retrospective study.
Nomoto H; Morimoto N; Miura K; Watanabe S; Takaoka Y; Maeda H; Sasaki T; Koyashiki Y; Kurata H; Numao N; Isoda N; Yamamoto H
BMC Gastroenterol; 2020 Dec; 20(1):427. PubMed ID: 33317473
[TBL] [Abstract][Full Text] [Related]
12. Lusutrombopag: First Global Approval.
Kim ES
Drugs; 2016 Jan; 76(1):155-8. PubMed ID: 26666417
[TBL] [Abstract][Full Text] [Related]
13. Lusutrombopag: A Review in Thrombocytopenia in Patients with Chronic Liver Disease Prior to a Scheduled Procedure.
Shirley M; McCafferty EH; Blair HA
Drugs; 2019 Oct; 79(15):1689-1695. PubMed ID: 31529283
[TBL] [Abstract][Full Text] [Related]
14. Thrombocytopenia in Chronic Liver Disease: New Management Strategies.
Nilles KM; Flamm SL
Clin Liver Dis; 2020 Aug; 24(3):437-451. PubMed ID: 32620282
[TBL] [Abstract][Full Text] [Related]
15. Lusutrombopag has slightly stronger effects on patients with mild thrombocytopenia compared with those with severe thrombocytopenia: A multicenter propensity score matching study.
Furuichi Y; Takeuchi H; Uojima H; Atsukawa M; Arai T; Arase Y; Kako M; Hidaka H; Itoi T
J Hepatobiliary Pancreat Sci; 2022 Apr; 29(4):439-448. PubMed ID: 34953107
[TBL] [Abstract][Full Text] [Related]
16. Relationship between baseline clinical characteristics and efficacy of lusutrombopag in thrombocytopenic patients with chronic liver disease:
Tanaka K; Baba T; Yoshida M; Iguchi M; Sonoyama T; Fukuhara T; Kano T
Curr Med Res Opin; 2022 Feb; 38(2):303-310. PubMed ID: 34904508
[TBL] [Abstract][Full Text] [Related]
17. Thrombopoietin receptor agonist is more effective than platelet transfusion for chronic liver disease with thrombocytopenia, shown by propensity score matching.
Furuichi Y; Takeuchi H; Yoshimasu Y; Kasai Y; Abe M; Itoi T
Hepatol Res; 2020 Sep; 50(9):1062-1070. PubMed ID: 32510789
[TBL] [Abstract][Full Text] [Related]
18. Role of severe thrombocytopenia in preventing platelet count recovery in thrombocytopenic patients with chronic liver disease.
Hirooka M; Ochi H; Hiraoka A; Koizumi Y; Tanaka T; Sunago K; Yukimoto A; Imai Y; Watanabe T; Yoshida O; Abe M; Joko K; Michitaka K; Hiasa Y
J Gastroenterol Hepatol; 2020 Feb; 35(2):299-304. PubMed ID: 31318996
[TBL] [Abstract][Full Text] [Related]
19. Systematic Review with Meta-Analysis: Efficacy and Safety of Lusutrombopag for Severe Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Invasive Procedures.
Orme ME; Bentley R; Marcella S; Peck-Radosavljevic M; Perard R; Wedemeyer H; Yoshiji H; Agarwal K; Dusheiko G
Adv Ther; 2022 Sep; 39(9):4169-4188. PubMed ID: 35836089
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Repeated Lusutrombopag Administration for Thrombocytopenia in a Patient Scheduled for Invasive Hepatocellular Carcinoma Treatment.
Sato S; Miyake T; Kataoka M; Isoda K; Yazaki T; Tobita H; Ishimura N; Kinoshita Y
Intern Med; 2017 Nov; 56(21):2887-2890. PubMed ID: 28943563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
